Picture: Vetter

Manufacturers respond to stricter regulations with novel approaches.

IN Carta image analysis software segmentation masks and heat maps of the SSc FMT markers and intensity features. Assay plates are imaged using the IN Cell Analyzer 6000 and IN Carta image analysis software from GE. Settings used: Nuclei
detection (Fast), Cell detection (Robust), and Organelles-Cells-Fibers. Our first assumption was to look at intensity related measures like intensity or density. This did not yield a very strong pattern for our control wells vs the samples and negative controls. Picture: GE Healthcare

Galapagos’s mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary healthy andpatient cells, the company discovers which proteins play a key role in diseases such as rheumatoid arthritis, inflammatory bowel disease, and fibrosis.

eb_2019_sponsored_lumentus.jpg

Oncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized.  But success relies on following a plan from the start — learn how in this free whitepaper

Picture: Lipidomics
LEA, the Lipidomics Excellence Award, was founded to strengthen life sciences through lipidomics.  Over the course of April, the LEA jury deliberated on the submitted projects to announce the three LEA awardees.
96-well EchoLUTION DNA extraction. 4 randomly chosen DNA preparations from 8 different mouse organ tissues (12 replicates each) were analyzed on an agarose gel and applied to qPCR detection. All samples were detected with high reproducibility (standard deviation

BioEcho develops single-spin and 96-well kits for the isolation of DNA. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents resulting in increased sensitivity and reliability of downstream analyses. Therefore, the risk of inhibition or complete failure of PCR applications is eliminated. The process does not require washing steps and is significantly faster than commonly used bind-wash-elute methods.

Interlocking technologies and flexible business models facilitate global partnerships. Picture: Shutterstock / Pogonici

Small- and medium-size European companies face the challenge of establishing global B2B activities in order to access relevant markets along the drug development value chain. YUMAB’s flexible business model for the development of fully human antibodies attracts corporations overseas and facilitates international partnerships.

euro-guide-2019.jpg

The 9th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.

© Eurofins CDMO

High-potency drugs present numerous opportunities for improved drug selectivity, efficacy and safety profiles, and represent a growing area of global development focus, for applications such as oncology and hormone-based treatments. Although this class of molecules offers numerous benefits to patients, they require particular care and attention in ensuring the safety for those involved in their manufacture and handling.

Picture: European Chemistry Partnering

Six times as many decision-makers attended the 3rd European Chemistry Partnering today- compared to the initial event two years ago: with participants from Brazil, Morocco and Australia, all six continents were represented for the first time. More than 2,000 partnering meetings formed the basis of interdisciplinary exchanges regarding innovation. In addition, there were countless discussions in the exhibition area, at the speaker corners and during the many networking opportunities.

Picture: Goodfellow

Leading global supplier of materials, Goodfellow, has collaborated with a number of major international companies to provide research materials in several industry sectors.